Nls Pharmaceutic - NLSPW STOCK NEWS

NLS Pharmaceutics (NLSP) announces a groundbreaking exclusive worldwide license agreement with Aexon Labs, Inc., acquiring global rights to Dual Orexin Receptor Agonists for neurological disorders. The agreement aims to develop compounds targeting orexin receptors for narcolepsy, hypersomnia, and neurodegenerative diseases. NLS plans to focus on disease-modifying compounds to enhance its neuroscience pipeline in sleep medicine.

NLS Pharmaceutics Ltd. announces CEO's attendance at BIO-EUROPE Springtime Partnering Event in Barcelona, Spain. The event aims to facilitate one-to-one meetings for over 3,700 attendees from 2,000+ companies.

NLS Pharmaceutics Ltd. (NLSP) regains compliance with Nasdaq listing requirements, given an additional 180 days to evidence compliance.

NLS Pharmaceutics Ltd. announces submission of plan to regain compliance with Nasdaq listing rule 5550(b)(1) after receiving notification of non-compliance due to minimum stockholders' equity requirement. Nasdaq may grant an extension of up to 180 days for compliance.

NLS Pharmaceutics Ltd. (NLSP) received a letter from Nasdaq notifying them of non-compliance with the minimum stockholders' equity requirement. They have 45 days to submit a plan to regain compliance and maintain their listing on the Nasdaq Capital Market.

NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) CEO Issues Letter to Shareholders, reporting on the progress made in 2023, including clinical successes, ongoing business development, leadership appointments, and generating pre-approval, non-dilutive revenues.

NLS Pharmaceutics Ltd. (NLSP) has entered into an exclusive worldwide option agreement with Aexon Labs, Inc. to acquire global development and commercialization rights to Aexon Labs' Dual Orexin Receptor Agonists platform. The agreement includes a potentially leading next-generation, first-in-class, oral, dual orexin receptor agonist (AEX-2) with expected clinical development in 2024. NLS will pay $30,000 for the option exclusivity and $170,000 upon execution of the definitive agreement to exercise the option. The transaction will be structured as an exclusive worldwide license for the development and commercialization by NLS of the Aexon Labs' compounds and their derivatives, with Aexon Labs receiving 15% of all proceeds earned by NLS in any future sub-licensing agreements. Eric Konofal, MD, PhD, who works under a part-time consulting agreement for NLS as its Chief Scientific Officer, is the president and founder of Aexon Labs, and owns 59% of Aexon Labs. Alexander Zwyer, Chief Executive Officer of NLS, owns 35% of Aexon Labs.

NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) announced the election of Dr. Florence Allouche Aknin and Dr. Claudio Basetti to join its board of directors effective January 1, 2024. The company aims to leverage their expertise in sleep medicine, pharmaceutical innovation, entrepreneurship, and fundraising to develop innovative therapies for patients with rare and complex central nervous system disorders.

NLS Pharmaceutics Ltd. (NLSP, NLSPW) to present at Oppenheimer Sleep Disorders Summit